tranScrip Appoints Rob Fox as Chief Commercial Officer to Drive Strategic Growth

tranScrip is delighted to announce the appointment of Rob Fox as Chief Commercial Officer. Rob brings over two decades of expertise in pharmaceutical services, specialising in commercial leadership, strategic development, and corporate growth.

Rob has held prominent leadership roles at Idis and Clinigen, where he played a key role in business development, investor relations, and corporate strategy. As a member of Clinigen’s Senior Leadership Team, Rob contributed significantly to advancing the company’s strategic vision and operational excellence. His career spans 21 years of commercial functions, working across therapeutic areas including oncology, CNS, infectious disease, immunology, and rare disease therapies.

Rob is recognised for his collaborative approach, partnering closely with clinical, medical, and commercial teams to ensure patients with unmet medical needs have access to transformative medicines. He has worked with over 15 of the top 20 global pharmaceutical companies and numerous mid-sized and emerging biotech firms, driving M&A activities, service expansions, and supporting clients throughout pre- and post-launch phases.

Mark Corbett, CEO of tranScrip, stated: “We are thrilled to welcome Rob to tranScrip during this exciting phase of our growth. Rob brings a wealth of experience, commercial insight, and strategic leadership that will be instrumental as we expand our services and continue delivering exceptional value to our clients. His appointment highlights our dedication to operational excellence and reinforces our position as a leader in providing impactful solutions for our clients and patients worldwide.”

Rob Fox commented on his appointment to tranScrip: “I am excited to join tranScrip during such an important stage of its growth journey. The company’s commitment to delivering innovative solutions across the products lifecycle aligns with my values and experience. I look forward to working with this exceptional team to continue to forge strong relationships with large and small pharma companies and ultimately make a meaningful positive impact on global healthcare and to patients.”

Robs proven leadership and strategic capabilities will play a crucial role in strengthening tranScrip’s commercial strategies and enhancing client partnerships.

For more insights about our leadership and team members, visit Our People.